Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

Several other brokerages have also recently weighed in on ACHN. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 10th. Jefferies Group LLC reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Maxim Group reduced their price objective on shares of Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Leerink Swann raised shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $4.00 to $6.00 in a research note on Thursday, May 18th. Finally, Robert W. Baird upped their price target on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, April 24th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Achillion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $8.75.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down 1.85% on Thursday, reaching $4.78. The company’s stock had a trading volume of 1,173,824 shares. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49. The firm has a 50 day moving average of $4.29 and a 200 day moving average of $4.09. The company’s market cap is $653.54 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. Analysts predict that Achillion Pharmaceuticals will post ($0.64) earnings per share for the current year.

WARNING: “Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Upgraded to Buy at BidaskClub” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/08/achillion-pharmaceuticals-inc-nasdaqachn-upgraded-to-buy-at-bidaskclub.html.

A number of hedge funds have recently modified their holdings of ACHN. Wells Fargo & Company MN boosted its stake in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 22,931 shares during the period. HealthInvest Partners AB purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter worth approximately $2,096,000. Deschutes Portfolio Strategy LLC boosted its stake in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 3,000 shares during the period. Bank of Montreal Can boosted its stake in shares of Achillion Pharmaceuticals by 12,296.5% in the first quarter. Bank of Montreal Can now owns 53,305 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 52,875 shares during the period. Finally, Creative Planning boosted its stake in shares of Achillion Pharmaceuticals by 2.0% in the first quarter. Creative Planning now owns 155,576 shares of the biopharmaceutical company’s stock worth $655,000 after buying an additional 3,000 shares during the period. 71.26% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.